Exmoor Pharma and Virica Gain Funding to Enhance Gene Therapies

The English and Canadian biopharmaceutical companies are combining their technologies in a joint project.

Written by Built In Staff, With AI
Published on Oct. 17, 2024
medicine
Photo: Shutterstock
REVIEWED BY
Ashley Bowden | Oct 17, 2024

Bristol-based eXmoor pharma and Ottawa-based Virica have received funding from a Canada-U.K. government biomanufacturing collaboration to enhance the development of adeno-associated vectors, or AAVs, which are a key element for gene therapies. The funding is part of an initiative to make gene therapy production more efficient and cost-effective. 

eXmoor specializes in accelerating the manufacturing journey, from research to patient access, within the cell-and-gene-therapy sector. Through the project, eXmoor and Virica develop and validate the abilities of Virica’s viral sensitizer enhancers, small molecules designed to boost AAV productivity. Leveraging eXmoor’s scaling process expertise, the companies will work to deploy the top candidates at a commercial scale upon completing the project in 2025.

The companies previously applied to the Canada-U.K. Biomanufacturing of Biologics and Advanced Therapies collaborative R&D competition. As a result, eXmoor will receive support through Innovate UK for the project, while Virica will receive advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program.

 

This article was written by Writer, a generative AI tool, using information from press releases and company blogs provided by our staff. All content was reviewed by a Built In editor and went through a fact-checking process to ensure accuracy. Errors can be reported to our team at [email protected].

Explore Job Matches.